Biomarin Pharmaceutical Stock News

Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.

BioMarin's Win In Phase 3 Hemophilia Study Makes Its Investment Case Stronger

Futures Resume Tumbling After Yields Spike To New 2 Year High The new week has picked up where last week left off: with futures selling off and global markets lower as yields continued their relentless treck higher, hitting fresh two year highs (amid concerns of a faster Fed balance sheet drawdown coupled with a massive IG issuance slate forcing managers to put on rate locks in what remains an illiquid market). US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am ... while Treasury yields stabilized after reversing an earlier spike rising as high as 1.8064% before dropping to 1.7656% following a global bond selloff last week as investors awaited key inflation data later in the week. Tech stocks again led the decline with Nasdaq futs down 0.63%, while Dow futures were down 0.12% or 44 points. The dollar rose, bitcoin dropped and crude oil steadied around $79 a barrel. Market volatility continues to grow almost everywhere, with lingering uncertainties keeping pressure on sentiment, said Pierre Veyret, technical analyst at ActivTrades. Traders are likely to wait for new major market drivers before pushing stock prices in new directions.

BioMarin Pharmaceutical Inc (NASDAQ: BMRN ) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A. Annualized Bleeding Rate (ABR) was significantly reduced by 4.1 treated bleeds per year in the pre-specified primary analysis in participants from a prior non-interventional study. Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII infusion rate Full story available on Benzinga.com

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.  Annualized

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced stable and durable annualized bleed control in phase 3 GENEr8-1 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A. The 134-participant study met all primary and secondary efficacy endpoints at two year analysis. In the study, Annualized Bleeding Rate was

BioMarin to Present at Two Investor Conferences in January 2022 SAN RAFAEL, Calif., Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac

These quiet biotechs are tightly focused and practically alone in their markets.

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQGM: AMRN)

(PR-inside.com) LOS ANGELES, CA / ACCESSWIRE / December 22, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company''s securities between January 13, 2020, and September 3, 2021, inclusive (the ''''Class Period''''), are encouraged to contact the firm before December 22, 2021. If you are a shareholder who suffered a loss, click here to participate. We also ..

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (BioMarin or the Company) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the Class Period). Such investors are encouraged to join this case by visiting the firms site: www.bgandg

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 22, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the "Class Period").Such investors are encouraged to join this case by visiting the firm''s site: www.bgandg.com/bmrn. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that ..

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 21, 2021 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ:BMRN) between January 13, 2020 and September 3, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?wire=1 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation ..